The U.S. Food and Drug Administration (FDA) updated the label for Guselkumab (Tremfya) on June 4, 2026. This revision expands the indication and usage to include pediatric patients aged 6 years and older who weigh at least 40 kg, for the treatment of moderate-to-severe plaque psoriasis.
Background
Guselkumab, marketed as Tremfya, is an interleukin-23 antagonist. Prior to this update, it was indicated for adults with moderate-to-severe plaque psoriasis. The drug works by targeting the interleukin-23 (IL-23) pathway, which is involved in inflammatory and immune responses associated with plaque psoriasis. The recent label revision specifically broadens the eligible patient population to include younger individuals who meet certain age and weight criteria, acknowledging the need for effective treatment options across different age groups for this chronic skin condition.
What this means
This label update for Guselkumab (Tremfya) signifies an important expansion of treatment options for pediatric patients suffering from moderate-to-severe plaque psoriasis. Clinicians can now consider Tremfya for patients as young as 6 years of age, provided they also meet the minimum weight requirement of 40 kg. This change addresses a critical need in pediatric dermatology, offering a targeted biologic therapy for a condition that can significantly impact quality of life in children and adolescents. The inclusion of this younger population reflects ongoing efforts to provide evidence-based treatments for chronic conditions across the lifespan.
Source
The information regarding this label revision for Tremfya was sourced from the U.S. Food and Drug Administration (FDA). The updated "Indication and usage" section became effective on June 4, 2026, and is publicly available on the dailymed.nlm.nih.gov website.